56.3 F
New York
Tuesday, May 17, 2022

Pfizer-BioNTech’s COVID19 Vaccine Candidate Acheive 95% Success

Must read

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have disclosed Wednesday that their COVID-19 vaccine candidate, BNT162b2, has shown a 95% efficacy rate in the final stage. The company has revealed that 170 cases were assessed in the trial. Out of 170, 162 were observed in placebo, and 8 were in the vaccine group.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


PFE and BNTX have observed that the efficacy rate remained constant across age, gender, race, and ethnicity demographics. The firms have found efficacy in adults over 65 years of age was over 94%.

Both the partners have earlier declared that their vaccine candidate has shown 90% effectiveness against SARS-CoV-2, a virus that causes COVID-19. All the 43,000 volunteers have shown no concerning symptoms after receiving the doses of vaccine.

BioNTech-Pfizer is planning to send the efficacy data to FDA and EUA and to health authorities around the world. Both the partners are anticipating to produce 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.

Shares of Pfizer Inc. (NYSE: PFE) went up 1.36% at $36.53 during the trading session of Wednesday. It had a trading volume of 46.3 million as compared to the average volume of 31.12 million. In the past 52-weeks of trading, this company share has changed between the 52-weeks low and high range of $26.42 and $39.79, respectively. This company has a total market capitalization of $194.77 billion at the time of writing.

More articles

Latest article